Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 300

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 300
---
, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities. II-1 Item 7. Recent Sales of Unregistered Securities. Set forth below are the sales of all unregistered securities of ours sold by us within the past three years (i.e., since November 25, 2022, up to the date of this registration statement) which were not registered under the Securities Act. We believe that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or Regulation S under the Securities Act. On January 11, 2024, we consummated a registered direct offering of 1,468,000 common shares and 32,000 pre-funded warrants at a price of $1.60 per common share and $1.5999 per pre-funded warrant share and a simultaneous private placement of unregistered common warrants to purchase an aggregate of up to 1,500,000 common shares. The unregistered common warrants have an exercise price of $1.60 per share, are immediately exercisable and have a 5-year term from the issuance date. On September 17, 2025, we entered into securities purchase agreements with investors, pursuant to which we shall issue and sell, from time to time, convertible promissory notes in the aggregate principal amount of up to $10,000,000. We had issued Promissory Notes in the aggregate principal amount of $2.5 million. As of the date hereof, all the outstanding amounts due under the Promissory Notes were converted into 5,171,460 Common Shares. The privately placed securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder since, among other things, the transactions did not involve a public offering and the securities were acquired for investment purposes only and not with a view to or for sale in connection with any distribution thereof. Additionally, since January 2022, we have granted share options and RSU’s to employees, directors, consultants and service providers under our Executive Stock Option and Restricted Share Unit Plans. There are currently an aggregate of 81,772 stock options and RSU’s outstanding, with exercise prices ranging from $23.40 to $642.03 per share. Item 8. Exhibits and Financial Statement Schedules. (a)